SIRPA and neoplasm: The direct effect of ROS on tumor cell proliferation or death unlikely contributes to tumor growth inhibition in the CD47-SIRPα blockade scenario, since without T cell-mediated immune response, the blockade cannot inhibit tumor growth at all (Fig. 2a, b).